Dupixent Lawsuits for T-Cell Lymphoma Side Effects

Were you diagnosed with Cutaneous T-Cell Lymphoma (CTCL) after using Dupixent (dupilumab)? You may be entitled to compensation.

Dupixent lawsuits are now being investigated on behalf of patients who developed serious side effects, including Cutaneous T-Cell Lymphoma, after taking this popular eczema and asthma medication. If you or a loved one used Dupixent and later developed CTCL or another form of T-Cell Lymphoma, our legal team at Levin Papantonio is ready to help you seek justice.

Do you Qualify?

👉 Call us now or fill out the form on this page for a free, no-obligation case review. There are no fees unless we win your case.

Dupixient T-Cell Lymphoma lawsuit

What Is Dupixent (dupilumab)?

Dupixent, also known by its generic name dupilumab, is a prescription drug approved by the FDA to treat conditions like:

  • Moderate to severe eczema (atopic dermatitis)
  • Asthma
  • Chronic rhinosinusitis with nasal polyps
  • Eosinophilic esophagitis

It works by blocking certain proteins involved in inflammation. While many patients have found relief with Dupixent, some have reported devastating side effects — including the development or worsening of Cutaneous T-Cell Lymphoma, a rare but aggressive form of cancer.

What Are Dupixent T-Cell Lymphoma Side Effects?

Patients and doctors have raised alarms about Dupixent possibly triggering or worsening T-cell lymphomas, especially CTCL. These are cancers that affect the immune system and often appear on the skin as rashes, lesions, or tumors.

Some of the warning signs of CTCL include:

  • Red, scaly patches or thick plaques on the skin
  • Itching or pain in affected areas
  • Swollen lymph nodes
  • Fatigue or weight loss

In certain cases, continued use of the drug made the cancer worse.

What We Know About the Dupixent Lawsuits

Lawsuits are being filed by individuals who used Dupixent and were later diagnosed with T-cell lymphoma. These lawsuits claim that:

  • The drug’s manufacturers, Sanofi and Regeneron, failed to warn patients and doctors about the potential risk of CTCL
  • Patients may have continued taking the drug while their cancer worsened
  • Earlier detection and treatment could have improved patient outcomes

As of now, these lawsuits are in the early stages, but the number of claims is expected to grow as more patients become aware of the link between Dupixent and T-Cell Lymphoma.

Research Linking Dupixent to T-Cell Lymphoma

Several medical reports and studies have suggested that Dupixent may be tied to an increased risk of CTCL.

  • A study published on April 6, 2024 (Hasan et al., 2024), looked at whether people with atopic dermatitis (AD) who were treated with the drug dupilumab had a higher risk of developing cutaneous T-cell lymphoma (CTCL) compared to those who didn’t take the drug. In their first model, which adjusted for age only, they found that people who took dupilumab had a 300% higher risk of getting CTCL compared to those who didn’t (OR 4.10). Even after they adjusted for more factors—like sex, ethnicity, and race, and removed people who had taken certain other immune-suppressing drugs—the risk was still more than two times higher (OR 3.20).
  • A second study using TriNetX data (Mandel et al., 2024) was published in August 2024 and followed a method similar to the first study by Hasan et al. The researchers excluded patients who had other inflammatory diseases or had taken biologic drugs that might be linked to lymphoma.After matching patients by age, race, and sex, they found that people with atopic dermatitis (AD) who were treated with dupilumab had a 350% higher risk of developing cutaneous T-cell lymphoma (CTCL) compared to those who weren’t treated with the drug (RR 4.59).
  • In June 2025, a study led by Sheng-Kai Ma and his team looked at the risk of blood cancers in asthma patients who started treatment with dupilumab compared to those who used a common asthma drug combo (ICS/LABA). This study (Ma et al., 2025), using data from TriNetX, did not include anyone with a history of atopic dermatitis (AD).

    After adjusting for things like age, gender, income, other health problems, and medicine use, the risk of CTCL was more than 4.5 times higher in the dupilumab group. Dupilumab was also linked to an overall increased risk of any type of lymphoma. When the researchers looked only at patients who had taken their medications for at least 16 weeks, the risk numbers went up even more, especially for combined mature T and NK cell lymphomas, a broader group of cancers including CTCL and other subtypes, which was over 14 times higher for dupilumab users.
  • A 2019 study published in the Journal of the American Academy of Dermatology, showed multiple patients saw CTCL symptoms accelerate while using dupilumab.
  • Case reports warning that Dupixent may “unmask” or worsen hidden lymphomas mistaken for eczema

These findings have pushed doctors to re-evaluate how and when to prescribe Dupixent — especially when patients show unusual skin reactions that don’t improve.

What Kind of Settlement Can You Expect?

Every case is different, and settlements depend on the severity of harm, medical expenses, and long-term impact. That said, if successful, a Dupixent lawsuit could recover damages for:

  • Past and future medical bills
  • Pain and suffering
  • Lost wages or earning ability
  • Wrongful death (in fatal cases)

There is no class action at this time. These are expected to be individual lawsuits or consolidated multidistrict litigation (MDL) cases.

Don’t wait. Reach out today for a free consultation.

👉 Time limits apply, and your right to compensation may expire.

What Can a Dupixent Lawyer Do for You?

Hiring an experienced pharmaceutical injury lawyer can help you:

  • Gather medical records and evidence
  • Connect with expert witnesses
  • File your claim on time
  • Negotiate for the highest possible compensation
  • Fight in court if necessary

At Levin Papantonio, we’ve handled some of the most high-profile drug injury cases in the country. Our attorneys know how to stand up to big pharmaceutical companies — and win.

Why Choose Levin Papantonio for Your Dupixent Lawsuit?

Levin Papantonio is one of the most respected law firms in the U.S. for mass tort and pharmaceutical litigation. Here’s what sets us apart:

  • Over 70 years of legal experience
  • More than $30 billion recovered for clients
  • National leaders in mass tort law
  • No upfront costs — we only get paid if you win

We treat every client with compassion and fight every case with power.

Am I Eligible to File a Dupixent Lawsuit?

You may be eligible if you:

  • Used Dupixent (dupilumab) as prescribed
  • Were later diagnosed with T-Cell Lymphoma, especially Cutaneous T-Cell Lymphoma
  • Experienced serious side effects or worsening symptoms
  • Are within your state’s statute of limitations

Even if you’re unsure, it’s worth reaching out. We’ll review your case for free and let you know your legal options.

👉 Call us now or fill out the form to get started. There’s no cost and no pressure.

Contact Us Today for a Free Case Review

If you or someone you love has suffered serious side effects after using Dupixent, you don’t have to face it alone. Let our team at Levin Papantonio fight for the justice and compensation you deserve.

📞 Call (888) 381-4847.
🖋️ Fill out the secure form on this page
💼 100% Free Consultation | No Fees Unless We Win